Core Insights - Insight Molecular Diagnostics Inc. (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing to lead the marketing efforts for its upcoming clinical kitted assay, GraftAssureDx, set to launch in 2026 [2][5][6] - The company aims to democratize access to molecular diagnostic testing, focusing initially on transplant rejection testing through its GraftAssure family of assays, which includes GraftAssureCore and GraftAssureIQ [5][11][14] - The addressable market for kitted transplant rejection testing is estimated at $1 billion, with GraftAssure tests measuring donor-derived cell-free DNA (dd-cfDNA), a key biomarker for transplant rejection [8][10] Company Overview - iMDx, formerly known as Oncocyte Corp., is a precision diagnostics technology company headquartered in Nashville, Tennessee, since June 2025 [12] - The company specializes in quantifying dd-cfDNA, which is widely recognized as a biomarker for transplant rejection [11][12] - GraftAssureCore is currently reimbursed by Medicare and performed at iMDx's CLIA-certified laboratory in Nashville, while GraftAssureIQ is available for research use only [7][14] Leadership and Experience - Steven Tahmooressi brings over 25 years of healthcare industry experience, having previously held significant roles at Astellas Pharma, Abbott Laboratories, and Bristol-Myers Squibb [3][4][6] - His expertise includes leading successful product launches in transplantation, oncology, and immunology across various global markets [5][6][9] Product Development and Market Strategy - iMDx is preparing for FDA authorization of GraftAssureDx in 2025, which will be a clinical molecular diagnostic test kit aimed at improving testing access for kidney transplant patients [5][7][14] - The company has invested three years in developing its kitted product for transplant rejection testing, indicating a strong commitment to this market segment [5][8]

Core Points - Myriad Genetics, Inc. will hold its second quarter 2025 earnings conference call on August 5, 2025, at 4:30 PM ET [1] - The company's quarterly earnings will be released the same day after market close [1] - Management will provide a financial overview and business update during the call [1] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Investor Information - A live webcast of the conference call will be available on Myriad's Investor Relations website [2] - Participants can register for the call to receive a dial-in number and unique PIN [2] - An archived version of the webcast will be accessible after the call [2]

Core Insights - Insight Molecular Diagnostics Inc. has rebranded from Oncocyte Corporation and relocated its headquarters to Nashville, Tennessee, with a new stock symbol "IMDX" effective June 18, 2025 [1][2][3] Company Strategy - The rebranding reflects the company's expanded strategic direction beyond oncology, now including a focus on transplant medicine, aiming to deliver a molecular diagnostic kit for kidney transplant patients [2][3] - The company targets a $1 billion addressable market for transplant rejection testing and is transitioning from product development to commercialization [3][4] Operational Changes - The relocation to Nashville aligns operations with the company's CLIA-certified lab and healthcare innovation hub, while maintaining a laboratory in Göttingen, Germany [4] - The company is unifying its transplant diagnostics under the GraftAssure brand, retiring the VitaGraft name [11][16] Product Development - The GraftAssure product line includes GraftAssureCore (lab-developed test), GraftAssureIQ (research-use-only kit), and GraftAssureDx (in vitro diagnostic kit in development) [11][12][16] - The company is actively participating in the European Society for Organ Transplantation (ESOT) Congress to promote its GraftAssureIQ pilot site program [7][9] Branding and Identity - The new logo symbolizes the company's commitment to healthcare providers and reflects its mission to provide insights through science [5][6] - The rebranding leverages existing rights to the name Insight Genetics, acquired in 2020, and emphasizes a healthcare provider-centric philosophy [5][6]

Company Announcement - Oncocyte Corp. will report its first quarter 2025 financial results after the market closes on May 12, 2025 [1] - A live Zoom webinar will be held at 2:00 p.m. PT on the same day to discuss the financial results [1][2] Investor Information - The webinar will include a Q&A session and requires registration for access [2] - An archived replay of the webinar will be available on Oncocyte's investor relations website after the call concludes [2] Company Overview - Oncocyte is a diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to enhance patient outcomes [3]